# US 2008/0188453 A1 · Mapk/erk kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188453 A1
- Document ID: US20080188453A1
- Status: Published application
- Kind: A1
- Application number: 11/932,615
- Filed: 2007-10-31
- Published: 2008-08-07
- Earliest claimed: 2006-10-31
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Mark E. Adams; Qing Dong; Stephen W. Kaldor; Toulik Kanouri; Michael B. Wallace
- Web page: https://patentgrep.com/patent/US20080188453A1

## CPC

- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

## Claims

### Claim 1

A compound having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
X is selected from the group consisting of —CR7R8—, —NR9—, —O— and —S—;
Y1 and Y2 are each independently selected from the group consisting of O, S and NR10;
R1 is selected from the group consisting of (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R2 is hydrogen or a substituent convertible in vivo to hydrogen;
R3 is selected from the group consisting of hydroxy, amino, (C1-10)alkylamino, (C1-10)alkoxyamino, hydroxy(C1-10)alkoxyamino, hydroxy(C1-10)alkylamino, cycloamino, sulfonamido, imino, (C2-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R4 is selected from the group consisting of hydrogen, (C1-10)alkoxy, (C4-12)aryloxy, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, hydroxy(C1-10)alkyl, carbonyl(C1-10)alkyl, thiocarbonyl(C1-10)alkyl, sulfonyl(C1-10)alkyl, sulfinyl(C1-10)alkyl, (C1-10)azaalkyl, imino(C1-10)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-10)alkyl, aryl(C1-10)alkyl, hetero(C1-10)aryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R5 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R5 and R4 are taken together to form a substituted or unsubstituted ring;
R6 is selected from the group consisting of hydrogen, heteroaryloxy, amino, (C1-10)alkylamino, (C1-10)alkyl, halo(C1-10)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C4-12)aryl and hetero(C1-10)aryl, each substituted or unsubstituted, provided that R6 is absent when the atom to which it is bound forms part of a double bond;
R7 and R8 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C1-10)alkoxy, (C4-12)aryloxy, hetero(C1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, hydroxy(C1-10)alkyl, carbonyl(C1-10)alkyl, thiocarbonyl(C1-10)alkyl, sulfonyl(C1-10)alkyl, sulfinyl(C1-10)alkyl, (C1-10)azaalkyl, imino(C1-10)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-10)alkyl, aryl(C1-10)alkyl, hetero(C1-10)aryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R7 and R3 or R4 are taken together to form a substituted or unsubstituted ring, provided that R8 is absent when the atom to which it is bound forms part of a double bond;
R9 is selected from the group consisting of hydrogen, (C1-10)alkylamino, sulfonamido, imino, (C1-10)alkyl, halo(C1-10)alkyl, hydroxy(C1-10)alkyl, carbonyl(C1-10)alkyl, sulfonyl(C1-10)alkyl, sulfinyl(C1-10)alkyl, (C1-10)azaalkyl, imino(C1-10)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-10)alkyl, aryl(C1-10)alkyl, hetero(C1-10)aryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R9 and R3 or R4 are taken together to form a substituted or unsubstituted ring, provided that R9 is absent when the atom to which it is bound forms part of a double bond; and
R10 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, hydroxy(C1-10)alkyl, imino(C1-10)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-10)alkyl, aryl(C1-10)alkyl, hetero(C1-10)aryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R10 and R3 or R4 are taken together to form a substituted or unsubstituted ring,
with the provisos that: (a) Y1 is not S when X is —C(NH2)═, Y2 is O, R2 is H, R3 is —NH-Ph, R5 is H and R6 is H; (b) R3 is not —OEt when X is —CH═, Y1 is O, Y2 is O, R2 is H, R4 is unsubstituted phenyl, R5 is H and R6 is H; and (c) X is not —C(CO-OMe)=when Y1 is O, Y2 is O, R2 is H, R3 is —OMe, R4 is —OMe and R6 is —CO—OMe.

### Claim 2 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl; and
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring.

### Claim 3 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl; and
R13 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R13 and R11 are taken together to form a substituted or unsubstituted ring.

### Claim 4 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
L is absent or a linker providing 1, 2, 3, 4, 5 or 6 atom separation between the atoms to which L is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl; and
R14 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-13)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted.

### Claim 5 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
L is absent or a linker providing 1, 2, 3, 4, 5 or 6 atom separation between the atoms to which L is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl; and
R15 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted.

### Claim 6 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
m is selected from the group consisting of 0, 1, 2, 3, 4, 5, and 6;
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl;
R15 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted; and
each R16 and R17 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or any two R16 and R17 are taken together to form a substituted or unsubstituted ring.

### Claim 7 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5; and
each R18 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or two R18 are taken together to form a substituted or unsubstituted ring.

### Claim 8 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
R18a and R18c are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted.

### Claim 9 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof.

### Claim 10 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof.

### Claim 11 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof.

### Claim 12 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl;
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring; and
each R18 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or two R18 are taken together to form a substituted or unsubstituted ring.

### Claim 13 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5; and
each R18 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or two R18 are taken together to form a substituted or unsubstituted ring.

### Claim 14 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5; and
each R18 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or two R18 are taken together to form a substituted or unsubstituted ring.

### Claim 15 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl; and
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring.

### Claim 16 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl; and
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring.

### Claim 17 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl;
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring; and
each R18 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or two R18 are taken together to form a substituted or unsubstituted ring.

### Claim 18 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl;
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring; and
each R18 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or two R18 are taken together to form a substituted or unsubstituted ring.

### Claim 19 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5; and
each R18 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or two R18 are taken together to form a substituted or unsubstituted ring.

### Claim 20 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl; and
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring.

### Claim 21 (depends on 1)

The compound according to claim 1 having the formula:
or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl;
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring; and
each R18 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or two R18 are taken together to form a substituted or unsubstituted ring.

### Claim 22

A process comprising:
reacting a compound having the formula
with a compound having the formula
under conditions that form a first reaction product having the formula
reacting the first reaction product with a compound having the formula
under conditions that form a second reaction product having the formula
wherein
R1 is selected from the group consisting of (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R2 is hydrogen or a substituent convertible in vivo to hydrogen;
R3 is selected from the group consisting of hydroxy, amino, (C1-10)alkylamino, (C1-10)alkoxyamino, hydroxy(C1-10)alkoxyamino, hydroxy(C1-10)alkylamino, cycloamino, sulfonamido, imino, (C2-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R4 is selected from the group consisting of hydrogen, (C1-10)alkoxy, (C4-12)aryloxy, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, hydroxy(C1-10)alkyl, carbonyl(C1-10)alkyl, thiocarbonyl(C1-10)alkyl, sulfonyl(C1-10)alkyl, sulfinyl(C1-10)alkyl, (C1-10)azaalkyl, imino(C1-10)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-10)alkyl, aryl(C1-10)alkyl, hetero(C1-10)aryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R5 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R5 and R4 are taken together to form a substituted or unsubstituted ring; and
LG1 and LG2 are each independently a leaving group.

### Claim 23 (depends on 22)

The process according to claim 22, further comprising:
treating the second reaction product under conditions that form a third reaction product having the formula

### Claim 24 (depends on 23)

The process according to claim 23, further comprising:
reacting the third reaction product with a compound having the formula
under conditions that form a product having the formula
wherein
R11 is hydrogen, a substituent convertible in vivo to hydrogen, a substituted or unsubstituted (C1-10)alkyl, or a substituted or unsubstituted halo(C1-10)alkyl; and
R12 is selected from the group consisting of hydrogen, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R11 and R12 are taken together to form a substituted or unsubstituted ring.

### Claim 25

A process comprising:
reacting a compound having the formula
with a compound having the formula
under conditions that form a product having the formula
wherein
R1 is selected from the group consisting of (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R2 is hydrogen or a substituent convertible in vivo to hydrogen;
R3 is selected from the group consisting of hydroxy, amino, (C1-10)alkylamino, (C1-10)alkoxyamino, hydroxy(C1-10)alkoxyamino, hydroxy(C1-10)alkylamino, cycloamino, sulfonamido, imino, (C2-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-13)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R4 is selected from the group consisting of hydrogen, (C1-10)alkoxy, (C4-12)aryloxy, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, hydroxy(C1-10)alkyl, carbonyl(C1-10)alkyl, thiocarbonyl(C1-10)alkyl, sulfonyl(C1-10)alkyl, sulfinyl(C1-10)alkyl, (C1-10)azaalkyl, imino(C1-10)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-10)alkyl, aryl(C1-10)alkyl, hetero(C1-10)aryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted; and
R5 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R5 and R4 are taken together to form a substituted or unsubstituted ring.

### Claim 26

A compound having the formula:
wherein
Y1 is selected from the group consisting of O, S and NR10;
R1 is selected from the group consisting of (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R2 is hydrogen or a substituent convertible in vivo to hydrogen;
R3 is selected from the group consisting of hydroxy, amino, (C1-10)alkylamino, (C1-10)alkoxyamino, hydroxy(C1-10)alkoxyamino, hydroxy(C1-10)alkylamino, cycloamino, sulfonamido, imino, (C2-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted;
R5 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R5 and R4 are taken together to form a substituted or unsubstituted ring; and
R10 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, hydroxy(C1-10)alkyl, imino(C1-10)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-10)alkyl, aryl(C1-10)alkyl, hetero(C1-10)aryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R10 and R3 or R4 are taken together to form a substituted or unsubstituted ring.

### Claim 27 (depends on 1)

The compound according to claim 1, wherein X is —N═.

### Claim 28 (depends on 1)

The compound according to claim 1, wherein X is —CR7═.

### Claim 29 (depends on 1)

The compound according to claim 1, wherein X is —O—.

### Claim 30 (depends on 1)

The compound according to claim 1, wherein Y1 is O.

### Claim 31 (depends on 1)

The compound according to claim 1, wherein Y1 and R3 are taken together to form a substituted or unsubstituted hetero(C1-6)aryl.

### Claim 32 (depends on 1)

The compound according to claim 1, wherein Y1 and R3 are taken together to form a substituted or unsubstituted triazolyl or oxadiazolyl.

### Claim 33 (depends on 1)

The compound according to claim 1, wherein Y2 is O.

### Claim 34 (depends on 1)

The compound according to claim 1, wherein R1 is selected from the group consisting of (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C4-12)aryl and hetero(C1-10)aryl, each substituted or unsubstituted.

### Claim 35 (depends on 1)

The compound according to claim 1, wherein R1 is selected from the group consisting of (C4-12)aryl and hetero(C1-10)aryl, each substituted or unsubstituted.

### Claim 36 (depends on 1)

The compound according to claim 1, wherein R1 is a substituted or unsubstituted (C4-12)aryl.

### Claim 37 (depends on 1)

The compound according to claim 1, wherein R1 is a substituted or unsubstituted phenyl.

### Claim 38 (depends on 1)

The compound according to claim 1, wherein R1 is a substituted or unsubstituted (C9-12)bicycloaryl.

### Claim 39 (depends on 1)

The compound according to claim 1, wherein R1 is a substituted or unsubstituted naphthyl.

### Claim 40 (depends on 1)

The compound according to claim 1, wherein R1 is a substituted or unsubstituted hetero(C4-12)bicycloaryl.

### Claim 41 (depends on 1)

The compound according to claim 1, wherein R1 is substituted with one or more substituents selected from the group consisting of hydrogen, halo, cyano, thio, alkoxy, (C1-3)alkyl, hydroxy(C1-3)alkyl and (C3-8)cycloalkyl, each substituted or unsubstituted.

### Claim 42 (depends on 1)

The compound according to claim 1, wherein R1 is substituted with one or more substituents selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, cyano, methylthio, methoxy, trifluoromethoxy, methyl, ethyl, trifluoromethyl, ethynyl, n-propanolyl and cyclopropyl.

### Claim 43 (depends on 1)

The compound according to claim 1, wherein R1 comprises:
wherein
R18a, R18b, R18c, R18d and R18e are each independently selected from the group consisting of hydrogen, halo, cyano, thio, alkoxy, (C1-3)alkyl and hydroxy(C1-3)alkyl, each substituted or unsubstituted.

### Claim 44 (depends on 1)

The compound according to claim 1, wherein R2 is hydrogen.

### Claim 45 (depends on 1)

The compound according to claim 1, wherein
R3 is R13O-L-,
L is absent or a linker providing 1, 2, 3, 4, 5 or 6 atom separation between the atoms to which L is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur; and
R13 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R13 and R11 are taken together to form a substituted or unsubstituted ring.

### Claim 46 (depends on 1)

The compound according to claim 1, wherein R4 is selected from the group consisting of amino, (C1-15)alkylamino, (C1-15)alkyl, halo(C1-5)alkyl, hydroxy(C1-5)alkyl, (C1-8)azaalkyl, hydroxy(C1-8)azaalkyl and (C3-6)cycloalkyl, each substituted or unsubstituted.

### Claim 47 (depends on 1)

The compound according to claim 1, wherein R5 is selected from the group consisting of hydrogen, (C1-5)alkyl, amino(C1-10)alkyl, hydroxy(C1-10)alkyl and (C3-12)cycloalkyl, each substituted or unsubstituted.

### Claim 48 (depends on 1)

The compound according to claim 1, wherein R5 is selected from the group consisting of (C1-5)alkyl and halo(C1-5)alkyl, each substituted or unsubstituted.

### Claim 49 (depends on 1)

The compound according to claim 1, wherein R5 is selected from the group consisting of (C1-5)alkyl, amino(C1-5)alkyl, carbonyl(C1-5)alkyl, hydroxy(C115)alkylalkoxy(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl and (C3-8)cycloalkyl, each substituted or unsubstituted.

### Claim 50 (depends on 1)

The compound according to claim 1, wherein R5 is selected from the group consisting of (C1-3)alkyl, (C1-3)alkylamino(C1-3)alkyl, di(C1-3)alkylamino(C1-3)alkyl, terahydrofuranyl(C1-3)alkyl, pyrrolidinolyl(C1-3)alkyl, thiazolidinyl(C1-3)alkyl, hydroxyl-(C1-3)alkan-one-yl, (C1-3)alkoxy-(C1-3)alkan-one-yl, (C1-5)alkenyl, hydroxy(C1-3)alkyl, N—(C1-3)alkoxy-acetamido(C1-3)alkyl, tetrahydro-2H-1,2-oxazine-one-yl-(C1-3)alkyl, N—((C1-3)alkylsulfinyl(C1-3)alkoxy)-amino(C1-3)alkyl, N—((C1-3)alkylsulfinyl(C1-3)alkyl)-amino(C1-3)alkyl, (C1-3)alkylsulfonyl(C1-3)alkoxy(C1-3)alkyl, imidazolidin-one-yl-(C1-3)alkyl, dihydroxy-(C1-5)alkyl and isoxazolidin-one-yl-(C1-3)alkyl, each substituted or unsubstituted.

### Claim 51 (depends on 1)

The compound according to claim 1, wherein R5 is selected from the group consisting of ethyl, propyl, n-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylaminomethyl, dimethylaminomethyl, terahydrofuranylmethyl, terahydrofuranylethyl, pyrrolidinolylmethyl, thiazolidinylmethyl, thiazolidinylethyl, hydroxyl-propan-one-yl, methoxy-propan-one-yl, butenyl, hydroxybutanyl, N-methoxy-acetamidomethyl, tetrahydro-2H-1,2-oxazine-one-yl-methyl, N-(methylsulfinylethoxy)-aminomethyl, N-(methylsulfinylpropyl)-aminomethyl, methylsulfonylethoxymethyl, imidazolidin-one-yl-ethyl, dihydroxy-butanyl and isoxazolidin-one-yl-methyl.

### Claim 52 (depends on 1)

The compound according to claim 1, wherein R5 is hydrogen.

### Claim 53 (depends on 1)

The compound according to claim 1, wherein R5 is methyl.

### Claim 54 (depends on 1)

The compound according to claim 1, wherein R6 is selected from the group consisting of hydrogen and a substituted or unsubstituted (C1-5)alkyl.

### Claim 55 (depends on 1)

The compound according to claim 1, wherein R6 is hydrogen.

### Claim 56 (depends on 1)

The compound according to claim 1, wherein R7 is hydrogen.

### Claim 57 (depends on 1)

The compound according to claim 1, wherein R7 is a substituted or unsubstituted (C1-3)alkyl.

### Claim 58 (depends on 1)

The compound according to claim 1, wherein R7 is halo.

### Claim 59 (depends on 1)

The compound according to claim 1, wherein R8 is hydrogen.

### Claim 60 (depends on 1)

The compound according to claim 1, wherein R9 is hydrogen.

### Claim 61 (depends on 1)

The compound according to claim 1, wherein R9 is selected from the group consisting of (C1-5)alkyl and halo(C1-5)alkyl, each substituted or unsubstituted.

### Claim 62 (depends on 1)

The compound according to claim 1, wherein R10 is a substituted or unsubstituted (C1-5)alkyl.

### Claim 63 (depends on 2)

The compound according to claim 2, wherein R11 is hydrogen.

### Claim 64 (depends on 2)

The compound according to claim 2, wherein R11 is selected from the group consisting of (C1-5)alkyl and halo(C1-5)alkyl, each substituted or unsubstituted.

### Claim 65 (depends on 2)

The compound according to claim 2, wherein R12 is selected from the group consisting of hydrogen, hydroxyl, alkoxy, (C1-10)alkyl, hydroxy(C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl and hetero(C1-10)aryl, each substituted or unsubstituted.

### Claim 66 (depends on 2)

The compound according to claim 2, wherein
R12 is R13O-L-,
L is absent or a linker providing 1, 2, 3, 4, 5 or 6 atom separation between the atoms to which L is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur; and
R13 is selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R13 and R11 are taken together to form a substituted or unsubstituted ring.

### Claim 67 (depends on 2)

The compound according to claim 2, wherein R12 is selected from the group consisting of triazolyl, oxadiazolyl and oxazolyl, each substituted or unsubstituted.

### Claim 68 (depends on 2)

The compound according to claim 2, wherein R12 is not taken together with R9 to form a ring.

### Claim 69 (depends on 3)

The compound according to claim 3, wherein R13 is selected from the group consisting of hydrogen, alkoxy, (C1-10)alkyl, hydroxy(C1-10)alkyl and hetero(C3-12)cycloalkyl(C1-10)alkyl, each substituted or unsubstituted.

### Claim 70 (depends on 4)

The compound according to claim 4, wherein L is a substituted or unsubstituted (C1-10)alkylene.

### Claim 71 (depends on 4)

The compound according to claim 4, wherein L is a substituted or unsubstituted (C1-3)alkylene.

### Claim 72 (depends on 4)

The compound according to claim 4, wherein
L is —(CR16R17)m—;
m is selected from the group consisting of 0, 1, 2, 3, 4, 5, and 6; and
each R16 and R17 is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C1-10)alkyl, halo(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, amino (C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or any two R16 and R17 are taken together to form a substituted or unsubstituted ring.

### Claim 73 (depends on 4)

The compound according to claim 4, wherein R14 is selected from the group consisting of hydroxyl, (C3-12)cycloalkyl and hetero(C3-12)cycloalkyl, each substituted or unsubstituted.

### Claim 74 (depends on 4)

The compound according to claim 4, wherein
R14 is —NR19R20; and
R19 and R20 are each independently selected from the group consisting of hydrogen, (C1-10)alkyl, halo(C1-10)alkyl, amino(C1-10)alkyl, imino(C1-3)alkyl, (C3-12)cycloalkyl(C1-5)alkyl, hetero(C3-12)cycloalkyl(C1-5)alkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl(C1-5)alkyl, hetero(C8-12)bicycloaryl(C1-5)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, (C9-12)bicycloalkyl, hetero(C3-12)bicycloalkyl, (C4-12)aryl, hetero(C1-10)aryl, (C9-12)bicycloaryl and hetero(C4-12)bicycloaryl, each substituted or unsubstituted, or R19 and R20 are taken together to form a substituted or unsubstituted ring.

### Claim 75 (depends on 74)

The compound according to claim 74, wherein R19 is hydrogen.

### Claim 76 (depends on 74)

The compound according to claim 74, wherein R20 is hydrogen.

### Claim 77 (depends on 5)

The compound according to claim 5, wherein R15 is selected from the group consisting of hydrogen and a substituted or unsubstituted (C1-5)alkyl.

### Claim 78 (depends on 6)

The compound according to claim 6, wherein m is 0.

### Claim 79 (depends on 6)

The compound according to claim 6, wherein m is 1.

### Claim 80 (depends on 6)

The compound according to claim 6, wherein each R16 is independently selected from the group consisting of hydrogen, hydroxyl, (C1-5)alkyl and hydroxy(C1-5)alkyl, each substituted or unsubstituted.

### Claim 81 (depends on 6)

The compound according to claim 6, wherein each R17 is independently selected from the group consisting of hydrogen, hydroxyl, (C1-5)alkyl and hydroxy(C1-5)alkyl, each substituted or unsubstituted.

### Claim 82 (depends on 7)

The compound according to claim 7, wherein n is 1.

### Claim 83 (depends on 7)

The compound according to claim 7, wherein n is 2.

### Claim 84 (depends on 7)

The compound according to claim 7, wherein each R18 is independently selected from the group consisting of hydrogen, halo, cyano, carbonyl, (C1-5)alkyl and (C3-12)cycloalkyl, each substituted or unsubstituted.

### Claim 85 (depends on 43)

The compound according to claim 43, wherein R18a is selected from the group consisting of hydrogen, halo, and a substituted or unsubstituted (C1-5)alkyl.

### Claim 86 (depends on 43)

The compound according to claim 43, wherein R18a is selected from the group consisting of fluoro, chloro and methyl.

### Claim 87 (depends on 43)

The compound according to claim 43, wherein R18c is selected from the group consisting of hydrogen, halo, cyano, thio, (C1-3)alkyl and hydroxy(C1-3)alkyl, each substituted or unsubstituted.

### Claim 88 (depends on 43)

The compound according to claim 43, wherein R18c is selected from the group consisting of iodo and bromo.

### Claim 89 (depends on 22)

The process according to claim 22, wherein LG1 is phenoxy.

### Claim 90 (depends on 22)

The process according to claim 22, wherein LG2 is halo.

### Claim 91 (depends on 1)

The compound according to claim 1 selected from the group consisting of:
5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid;
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1H-pyrrole-3-carboxamide;
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxylic acid;
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-N-(3-hydroxypropoxy)-1-methyl-1H-pyrrole-3-carboxamide;
(R)-5-Acetyl-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
(S)-5-Acetyl-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-N-(3-hydroxy-2-(hydroxymethyl)propoxy)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-4-chloro-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxylic acid;
(R)-5-Acetyl-4-chloro-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
(S)-5-Acetyl-4-chloro-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-4-chloro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-N-(1,3-dihydroxypropan-2-yloxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-N-(2,3-dihydroxypropyl)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-N-(3-hydroxypropyl)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-N-methoxy-N,1-dimethyl-1H-pyrrole-3-carboxamide;
1-(5-(2-Fluoro-4-iodophenylamino)-4-(4-hydroxyisoxazolidine-2-carbonyl)-1-methyl-1H-pyrrol-2-yl)ethanone;
(R)-5-Acetyl-N-(2,4-dihydroxybutoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
(S)-5-Acetyl-N-(2,4-dihydroxybutoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
1-(4-(Azetidine-1-carbonyl)-5-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrol-2-yl)ethanone;
1-(4-(3-Aminoazetidine-1-carbonyl)-5-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrol-2-yl)ethanone;
(S)-1-(5-(2-Fluoro-4-iodophenylamino)-4-(3-(hydroxymethyl)pyrrolidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl)ethanone;
1-(5-(2-Fluoro-4-iodophenylamino)-4-(2-(hydroxymethyl)azetidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl)ethanone;
(R)-1-(5-(2-Fluoro-4-iodophenylamino)-4-(3-(hydroxymethyl)pyrrolidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl)ethanone;
1-(4-((2R,3S,4S)-3,4-Dihydroxy-2-(hydroxymethyl)pyrrolidine-1-carbonyl)-5-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrol-2-yl)ethanone;
1-[5-(2-Fluoro-4-iodo-phenylamino)-4-(3-hydroxy-azetidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl]-ethanone;
1-[5-(2-Fluoro-4-iodo-phenylamino)-4-((R)-3-hydroxy-pyrrolidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl]-ethanone;
1-[5-(2-Fluoro-4-iodo-phenylamino)-4-((S)-3-hydroxy-pyrrolidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl]-ethanone;
1-[5-(2-Fluoro-4-iodo-phenylamino)-1-methyl-4-(pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl]-ethanone;
1-[5-(2-Fluoro-4-iodo-phenylamino)-4-((S)-2-hydroxymethyl-pyrrolidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl]-ethanone;
1-[5-(2-Fluoro-4-iodo-phenylamino)-4-((R)-2-hydroxymethyl-pyrrolidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl]-ethanone;
1-[4-(3-(R)-Amino-pyrrolidine-1-carbonyl)-5-(2-fluoro-4-iodo-phenylamino)-1-methyl-1H-pyrrol-2-yl]-ethanone;
Methanesulfonic acid 1-[5-acetyl-2-(2-fluoro-4-iodo-phenylamino)-1-methyl-1H-pyrrole-3-carbonyl]-azetidin-3-yl ester;
1-{5-(2-Fluoro-4-iodo-phenylamino)-4-[3-(2-hydroxy-ethylamino)-azetidine-1-carbonyl]-1-methyl-1H-pyrrol-2-yl}-ethanone;
1-(5-(2-Fluoro-4-iodo-phenylamino)-4-{3-[(2-hydroxy-ethyl)-methyl-amino]-azetidine-1-carbonyl}-1-methyl-1H-pyrrol-2-yl)-ethanone;
1-[4-(3-Dimethylamino-azetidine-1-carbonyl)-5-(2-fluoro-4-iodo-phenylamino)-1-methyl-1H-pyrrol-2-yl]-ethanone;
1-[5-(2-Fluoro-4-iodo-phenylamino)-4-(3-hydroxy-3-hydroxymethyl-azetidine-1-carbonyl)-1-methyl-1H-pyrrol-2-yl]-ethanone;
Ethyl 5-acetyl-4-fluoro-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxylate;
5-Acetyl-4-fluoro-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxylic acid;
(R)-5-Acetyl-N-(2,3-dihydroxypropoxy)-4-fluoro-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
(S)-5-acetyl-N-(2,3-dihydroxypropoxy)-4-fluoro-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-2-(4-bromo-2-fluorophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-5-propionyl-1H-pyrrole-3-carboxamide;
2-(2-fluoro-4-iodophenylamino)-5-(2-fluoroacetyl)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
5-(2,2-difluoroacetyl)-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-5-(2,2,2-trifluoroacetyl)-1H-pyrrole-3-carboxamide;
5-(2-fluoro-4-iodophenylamino)-N4-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-2,4-dicarboxamide;
5-(2-fluoro-4-iodophenylamino)-N4-(2-hydroxyethoxy)-N2,1-dimethyl-1H-pyrrole-2,4-dicarboxamide;
5-(cyclopropanecarbonyl)-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
5-acetyl-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,4-dimethyl-1H-pyrrole-3-carboxamide;
5-acetyl-4-fluoro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
1-(5-acetyl-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrol-3-yl)-2-hydroxyethanone;
2-(2-fluoro-4-iodophenylamino)-5-(2-hydroxyacetyl)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-5-(3-hydroxypropanoyl)-1-methyl-1H-pyrrole-3-carboxamide;
2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-5-(2-(methylamino)acetyl)-1H-pyrrole-3-carboxamide;
5-(2-(dimethylamino)acetyl)-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-5-(2-(2-hydroxyethylamino)acetyl)-1-methyl-1H-pyrrole-3-carboxamide;
2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide;
5-(2-fluoro-4-iodophenylamino)-N4-(2-hydroxyethoxy)-N2,1-dimethyl-1H-imidazole-2,4-dicarboxamide;
5-(2-fluoro-4-iodophenylamino)-N4-(2-hydroxyethoxy)-1-methyl-1H-imidazole-2,4-dicarboxamide;
5-(2-fluoro-4-iodophenylamino)-2-(2-hydroxyacetyl)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide;
5-acetyl-2-(2-chloro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
5-acetyl-N-(2-hydroxyethoxy)-2-(4-iodo-2-methylphenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-acetyl-2-(4-bromo-2-chlorophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
5-acetyl-2-(2-fluoro-4-iodophenylamino)-N-hydroxy-1-methyl-1H-pyrrole-3-carboxamide;
5-acetyl-N-(2-(dimethylamino)ethoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-acetyl-N-(cyclopropylmethoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
1-(5-(2-fluoro-4-iodophenylamino)-1-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)ethanone;
1-(5-(2-fluoro-4-iodophenylamino)-1-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrrol-2-yl)ethanone;
5-acetyl-2-(2-fluoro-4-iodophenylamino)-1-methyl-N-(1,2,4-oxadiazol-5-yl)-1H-pyrrole-3-carboxamide;
5-acetyl-2-(2-fluoro-4-iodophenylamino)-1-methyl-N-(1,3,4-oxadiazol-2-yl)-1H-pyrrole-3-carboxamide;
5-acetyl-2-(2-fluoro-4-iodophenylamino)-1-methyl-N-(oxazol-2-yl)-1H-pyrrole-3-carboxamide; and
5-acetyl-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethyl)-1-methyl-1H-pyrrole-3-carboxamide.

### Claim 92 (depends on 1)

The compound according to claim 1 selected from the group consisting of:
5-Acetyl-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrole-3-carboxamide;
(R)-5-Acetyl-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
(S)-5-Acetyl-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
(R)-5-Acetyl-4-chloro-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
(S)-5-Acetyl-4-chloro-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
5-Acetyl-N-(1,3-dihydroxypropan-2-yloxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide;
(R)-5-Acetyl-N-(2,3-dihydroxypropoxy)-4-fluoro-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide; and
(S)-5-acetyl-N-(2,3-dihydroxypropoxy)-4-fluoro-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxamide.

### Claim 93 (depends on 1)

The compound according to claim 1, wherein the compound is in the form of a pharmaceutically acceptable salt.

### Claim 94 (depends on 1)

The compound according to claim 1, wherein the compound is present in a mixture of stereoisomers.

### Claim 95 (depends on 1)

The compound according to claim 1, wherein the compound comprises a single stereoisomer.

### Claim 96 (depends on 1)

A pharmaceutical composition comprising as an active ingredient a compound according to claim 1.

### Claim 97 (depends on 96)

The pharmaceutical composition according to claim 96, wherein the composition is a solid formulation adapted for oral administration.

### Claim 98 (depends on 96)

The pharmaceutical composition according to claim 96, wherein the composition is a liquid formulation adapted for oral administration.

### Claim 99 (depends on 96)

The pharmaceutical composition according to claim 96, wherein the composition is a tablet.

### Claim 100 (depends on 96)

The pharmaceutical composition according to claim 96, wherein the composition is a liquid formulation adapted for parenteral administration.

### Claim 101 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, and intrathecally.

### Claim 102 (depends on 1)

A kit comprising:
a compound according to claim 1; and
instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound.

### Claim 103 (depends on 102)

The kit of claim 102, wherein the kit comprises the compound in a multiple dose form.

### Claim 104 (depends on 1)

An article of manufacture comprising:
a compound according to claim 1; and
packaging materials.

### Claim 105 (depends on 104)

The article of manufacture of claim 104, wherein the packaging material comprises a container for housing the compound.

### Claim 106 (depends on 105)

The article of manufacture of claim 105, wherein the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the compound.

### Claim 107 (depends on 104)

The article of manufacture of claim 104, wherein the article of manufacture comprises the compound in a multiple dose form.

### Claim 108 (depends on 1)

A therapeutic method comprising administering a compound according to claim 1 to a subject.

### Claim 109 (depends on 1)

A method of inhibiting a Mitogen-Activated Protein Kinase (MEK) comprising contacting the MEK with a compound according to claim 1.

### Claim 110 (depends on 1)

A method of inhibiting Mitogen-Activated Protein Kinase (MEK) comprising causing a compound according to claim 1 to be present in a subject in order to inhibit the MEK in vivo.

### Claim 111 (depends on 1)

A method of inhibiting Mitogen-Activated Protein Kinase (MEK) comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits the MEK in vivo, the second compound being a compound according to claim 1.

### Claim 112 (depends on 1)

A method of treating a disease state for which a Mitogen-Activated Protein Kinase (MEK) possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising causing a compound according to claim 1 to be present in a subject in a therapeutically effective amount for the disease state.

### Claim 113 (depends on 1)

A method of treating a disease state for which a Mitogen-Activated Protein Kinase (MEK) possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising administering a compound according to claim 1 to a subject, wherein the compound is present in the subject in a therapeutically effective amount for the disease state.

### Claim 114 (depends on 1)

A method of treating a disease state for which a Mitogen-Activated Protein Kinase (MEK) possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits the MEK in vivo, the second compound being a compound according to claim 1.

### Claim 115 (depends on 112)

The method according to claim 112, wherein the disease state is selected from the group consisting of cancerous hyperproliferative disorders; non-cancerous hyperproliferative disorders; pancreatitis; kidney disease; pain; preventing blastocyte implantation; treating diseases related to vasculogenesis or angiogenesis; asthma; neutrophil chemotaxis; septic shock; T-cell mediated diseases where immune suppression would be of value; atherosclerosis; and inhibition of keratinocyte responses to growth factor cocktails.

### Claim 116 (depends on 115)

The method of claim 115, wherein the hyperproliferative disorder is cancer.

### Claim 117 (depends on 116)

The method of claim 116, wherein the cancer is selected from the group consisting of brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, epidermoid, esophageal, testicular, gynecological or thyroid cancer.

### Claim 118 (depends on 115)

The method of claim 115, wherein the hyperproliferative disorder is selected from the group consisting of benign hyperplasia of the skin, restenosis, and benign prostatic hypertrophy (BPH).

### Claim 119 (depends on 118)

The method of claim 118, wherein the benign hyperplasia of the skin is psoriasis.

### Claim 120 (depends on 115)

The method of claim 115, wherein the disease related to vasculogenesis or angiogenesis is selected from the group consisting of tumor angiogenesis and acute or chronic inflammatory diseases.

### Claim 121 (depends on 115)

The method of claim 115, wherein the disease related to vasculogenesis or angiogenesis is selected from the group consisting of rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

### Claim 122 (depends on 109)

The method according to claim 109, wherein the MEK is MEK1.

### Claim 123 (depends on 109)

The method according to claim 109, wherein the MEK is MEK2.

### Claim 124 (depends on 1)

A method of inhibiting an Extracellular Regulated Kinase (ERK) comprising contacting the ERK with a compound according to claim 1.

### Claim 125 (depends on 1)

A method of inhibiting Extracellular Regulated Kinase (ERK) comprising causing a compound according to claim 1 to be present in a subject in order to inhibit the ERK in vivo.

### Claim 126 (depends on 1)

A method of inhibiting Extracellular Regulated Kinase (ERK) comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits the ERK in vivo, the second compound being a compound according to claim 1.

### Claim 127 (depends on 124)

The method according to claim 124, wherein the ERK is ERK1.

### Claim 128 (depends on 124)

The method according to claim 124, wherein the ERK is ERK2.
